The therapeutic options for locally advanced and advanced prostate cancer have increased and improved in the last several years. These therapeutic advancements have led to increased overall survival in both castration-resistant and castration-naive disease. Next generation imaging (NGI) techniques have also impacted diagnostic and therapeutic decision-making. With these changes, clinicians need clarity on the best available information and best practices to treat prostate cancer.
To address this challenge, the Radiographic Assessments for Detection of Advanced Recurrence (RADAR) III Group met to offer guidance and develop new guidelines on the use of NGI to stage prostate cancer based on available data and clinical experience. They also discussed the potential impact of NGIs on treatment options based on earlier detection of disease.
This Grand Rounds in Urology slide deck was developed from the RADAR III manuscript just published in the Journal of Urology. The RADAR III group recommended NGI techniques for select patients suspected of disease progression. This information is based on clinical judgement and laboratory (biomarker) values, comorbidities, and symptoms.
Ongoing research for additional NGI technologies may offer improved diagnostic accuracy and therapeutic options. As NGI techniques evolve and global accessibility improves, a clinician’s ability to more accurately stage the disease will enhance both decision-making and patient outcomes. We hope you will find this slide deck valuable in explaining novel next generation imaging techniques.
Crawford ED, Koo PJ, Shore N, et al. A Clinician’s Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). J Urol.2019 Jan 18. [Epub ahead of print].